 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT 
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?"
  }
}
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?",
    "drug": "CARBAMAZEPINE"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: CARBAMAZEPINE: drug_interactions: Chloroquine and Mefloquine Anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine. Thus if a patient has been 
titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with carbamazepine extended-release capsules, it is reasonable to expect that a dose adjustment
may be necessary. CNS Depressants The concomitant use of carbamazepine extended-release capsules and other CNS depressants can increase the risk of respiratory depression, profound sedation, 
hypotension, and syncope. CARBAMAZEPINE: drug_interactions: CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, 
antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. Consider reducing the dose of CNS depressants or 
carbamazepine extended-release capsules when using these drugs concomitantly. Because of its primary CNS effect, caution should be used when carbamazepine extended-release capsules are taken with 
other centrally acting drugs and alcohol. Neuromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, 
rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. CARBAMAZEPINE: drug_interactions: Whether or not carbamazepine has the same effect on other 
nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher. CARBAMAZEPINE: 
precautions: Whether or not carbamazepine has the same effect on other nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than 
expected, and infusion rate requirements may be higher. Carcinogenesis, Mutagenesis, Impairment of Fertility: Administration of carbamazepine to Sprague-Dawley rats for two years in the diet at doses 
of 25, 75, and 250 mg/kg/day (low dose approximately 0.2 times the maximum human daily dose of 1,200 mg on a mg/m 2 basis), resulted in a dose-related increase in the incidence of hepatocellular 
tumors in females and of benign interstitial cell adenomas in the testes of males. Carbamazepine must, therefore, be considered to be carcinogenic in Sprague-Dawley rats. Bacterial and mammalian 
mutagenicity studies using carbamazepine produced negative results. CARBAMAZEPINE: precautions: The significance of these findings relative to the use of carbamazepine in humans is, at present, 
unknown. Usage in Pregnancy (See WARNINGS ) Labor and Delivery The effect of carbamazepine on human labor and delivery is unknown. Nursing Mothers Carbamazepine and its epoxide metabolite are 
transferred to breast milk and during lactation. The concentrations of carbamazepine and its epoxide metabolite are approximately 50% of the maternal plasma concentration. Because of the potential for
serious adverse reactions in nursing infants from carbamazepine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to 
the mother. CARBAMAZEPINE: pediatric_use: Pediatric Use Substantial evidence of carbamazepine effectiveness for use in the management of children with epilepsy (see INDICATIONS for specific seizure 
types) is derived from clinical investigations performed in adults and from studies in several in vitro systems which support the conclusion that (1) the pathogenic mechanisms underlying seizure 
propagation are essentially identical in adults and children, and (2) the mechanism of action of carbamazepine in treating seizures is essentially identical in adults and children. Taken as a whole, 
this information supports a conclusion that the generally acceptable therapeutic range of total carbamazepine in plasma (i.e., 4 to 12 mcg/mL) is the same in children and adults. The evidence 
assembled was primarily obtained from short-term use of carbamazepine. The safety of carbamazepine in children has been systematically studied up to 6 months. No longer term data from clinical trials 
is available.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: information_for_patients: Information for Patients Patients should be informed of the availability of a Medication Guide and they should be instructed to read the Medication 
Guide before taking carbamazepine extended-release capsules. Patients should be made aware of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy and petechial or purpuric hemorrhage, and in the case of 
liver reactions, anorexia, nausea/vomiting, or jaundice. Patients should be advised that, because these signs and symptoms may signal a serious reaction, they must report any occurrence immediately to
their physicians. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use. CARBAMAZEPINE: 
information_for_patients: Patients should be advised that serious skin reactions have been reported in association with carbamazepine extended-release capsules. In the event a skin reaction should 
occur while taking carbamazepine extended-release capsules, patients should consult with their physician immediately (see WARNINGS ). Patients should be advised that anaphylactic reactions and 
angioedema may occur during treatment with carbamazepine extended-release capsules (see WARNINGS ). Advise patients to immediately report signs and symptoms suggesting angioedema (swelling of the 
face, eyes, lips, or tongue, or difficulty in swallowing or breathing) and to stop taking the drug until they have consulted with their healthcare provider. CARBAMAZEPINE: information_for_patients: 
Patients, their caregivers, and families should be counseled that AEDs, including carbamazepine, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert 
for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern 
should be reported immediately to healthcare providers. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use 
of any other prescription or nonprescription medications or herbal products. Caution should be exercised if alcohol is taken in combination with carbamazepine therapy, due to a possible additive 
sedative effect. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks. 
CARBAMAZEPINE: information_for_patients: Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of 
antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 (see Warnings-Usage in Pregnancy ). If necessary, the carbamazepine extended-release capsules can
be opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbamazepine extended-release capsules or their contents should not be crushed or 
chewed. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use of any other prescription or non-prescription 
medication or herbal products. Patients, their caregivers, and families should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior 
to taking carbamazepine extended-release capsules. CARBAMAZEPINE: information_for_patients: See FDA approved Medication Guide.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: pharm_class_pe         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: package_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_set_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: product_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: drug_interactions: When used concomitantly with carbamazepine extended-release capsules, monitoring of concentrations or dosage adjustment of these agents may be necessary: 
When carbamazepine is added to aripiprazole, the aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. If carbamazepine is later withdrawn, the 
aripiprazole dose should be reduced. When carbamazepine is used with tacrolimus, monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are recommended. The use of 
concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. If patients must be coadministered carbamazepine with temsirolimus, an adjustment of temsirolimus dosage 
should be considered. The use of carbamazepine with lapatinib should generally be avoided. CARBAMAZEPINE: drug_interactions: If carbamazepine is started in a patient already taking lapatinib, the dose
of lapatinib should be gradually titrated up. If carbamazepine is discontinued, the lapatinib dose should be reduced. Concomitant use of carbamazepine with nefazodone results in plasma concentrations 
of nefazodone and its active metabolite insufficient to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS ). Monitor 
concentrations of valproate when carbamazepine extended-release capsules are introduced or withdrawn in patients using valproic acid. CARBAMAZEPINE: drug_interactions: In addition, carbamazepine 
causes, or would be expected to cause, decreased levels of, for example, the following drugs, for which monitoring of concentrations or dosage adjustment may be necessary: Acetaminophen, albendazole, 
alprazolam, aprepitant, buprenorphine, apixaban( 6 ), bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, dabigatran( 6 
), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g. CARBAMAZEPINE: drug_interactions: felodipine), doxycycline, edoxaban( 6 ), eslicarbazepine, 
ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine,
oral and other hormonal contraceptives( 2 ), oxcarbazepine, paliperidone, phenytoin( 3 ), praziquantel, protease inhibitors, quetiapine, risperidone, rivaroxaban( 6 ), sertraline, sirolimus, 
tadalafil, theophylline, tiagabine, topiramate, tramadol, triazolam, trazodone CARBAMAZEPINE: drug_interactions: ( 4 ), tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), 
valproate, warfarin (5) , ziprasidone, and zonisamide. ( 2 ) Concomitant use of carbamazepine with hormonal contraceptive products (e.g., oral and levonorgestrel subdermal implant contraceptives) may 
render the contraceptives less effective because the plasma concentrations of the hormones may be decreased. Breakthrough bleeding and unintended pregnancies have been reported with carbamazepine. 
Alternative or back-up methods of contraception should be considered. ( 3 ) Phenytoin has also been reported to increase in the presence of carbamazepine. Careful monitoring of phenytoin plasma levels
following co-medication with carbamazepine is advised.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: warnings: However, in the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. Suicidal Behavior and Ideation 
Antiepileptic drugs (AEDs), including carbamazepine extended-release capsules, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated 
with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 
placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 
95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. CARBAMAZEPINE: warnings: In these trials, which had a median treatment duration of 12 weeks, the estimated
incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case
of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to 
allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted
for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. 
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. CARBAMAZEPINE: warnings: The finding of increased risk with AEDs of varying mechanisms of action 
and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table
1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1 - Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 
Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 
Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0. CARBAMAZEPINE: warnings: 9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in 
clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone 
considering prescribing carbamazepine extended-release capsules or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other 
illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts or behavior. Should suicidal thoughts and behavior emerge 
during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. CARBAMAZEPINE: warnings: Hyponatremia, 
Syndrome of Inappropriate Antidiuretic Hormone Secretion, and Water Intoxication Hyponatremia can occur as a result of treatment with carbamazepine extended-release capsules. In many cases, this 
hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment may be dose-related. Elderly 
patients and patients treated with diuretics are at greater risk of developing hyponatremia. Signs and symptoms of hyponatremia include headache, new or increased seizure frequency, difficulty 
concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Consider discontinuing carbamazepine extended-release capsules in patients with symptomatic 
hyponatremia. Usage in Pregnancy Carbamazepine can cause fetal harm when administered to a pregnant woman.         
SOURCE:CARBAMAZEPINE label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          )  DO-NOT-KNOW
*(FDAHandler)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?",
    "drug": "CARBAMAZEPINE"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT 
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?"
  }
}
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?",
    "drug": "CARBAMAZEPINE"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
CONTENT: CARBAMAZEPINE: drug_interactions: Chloroquine and Mefloquine Anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine. Thus if a patient has been 
titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with carbamazepine extended-release capsules, it is reasonable to expect that a dose adjustment
may be necessary. CNS Depressants The concomitant use of carbamazepine extended-release capsules and other CNS depressants can increase the risk of respiratory depression, profound sedation, 
hypotension, and syncope. CARBAMAZEPINE: drug_interactions: CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, 
antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. Consider reducing the dose of CNS depressants or 
carbamazepine extended-release capsules when using these drugs concomitantly. Because of its primary CNS effect, caution should be used when carbamazepine extended-release capsules are taken with 
other centrally acting drugs and alcohol. Neuromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, 
rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. CARBAMAZEPINE: drug_interactions: Whether or not carbamazepine has the same effect on other 
nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher. CARBAMAZEPINE: 
precautions: Whether or not carbamazepine has the same effect on other nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than 
expected, and infusion rate requirements may be higher. Carcinogenesis, Mutagenesis, Impairment of Fertility: Administration of carbamazepine to Sprague-Dawley rats for two years in the diet at doses 
of 25, 75, and 250 mg/kg/day (low dose approximately 0.2 times the maximum human daily dose of 1,200 mg on a mg/m 2 basis), resulted in a dose-related increase in the incidence of hepatocellular 
tumors in females and of benign interstitial cell adenomas in the testes of males. Carbamazepine must, therefore, be considered to be carcinogenic in Sprague-Dawley rats. Bacterial and mammalian 
mutagenicity studies using carbamazepine produced negative results. CARBAMAZEPINE: precautions: The significance of these findings relative to the use of carbamazepine in humans is, at present, 
unknown. Usage in Pregnancy (See WARNINGS ) Labor and Delivery The effect of carbamazepine on human labor and delivery is unknown. Nursing Mothers Carbamazepine and its epoxide metabolite are 
transferred to breast milk and during lactation. The concentrations of carbamazepine and its epoxide metabolite are approximately 50% of the maternal plasma concentration. Because of the potential for
serious adverse reactions in nursing infants from carbamazepine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to 
the mother. CARBAMAZEPINE: pediatric_use: Pediatric Use Substantial evidence of carbamazepine effectiveness for use in the management of children with epilepsy (see INDICATIONS for specific seizure 
types) is derived from clinical investigations performed in adults and from studies in several in vitro systems which support the conclusion that (1) the pathogenic mechanisms underlying seizure 
propagation are essentially identical in adults and children, and (2) the mechanism of action of carbamazepine in treating seizures is essentially identical in adults and children. Taken as a whole, 
this information supports a conclusion that the generally acceptable therapeutic range of total carbamazepine in plasma (i.e., 4 to 12 mcg/mL) is the same in children and adults. The evidence 
assembled was primarily obtained from short-term use of carbamazepine. The safety of carbamazepine in children has been systematically studied up to 6 months. No longer term data from clinical trials 
is available.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: information_for_patients: Information for Patients Patients should be informed of the availability of a Medication Guide and they should be instructed to read the Medication 
Guide before taking carbamazepine extended-release capsules. Patients should be made aware of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy and petechial or purpuric hemorrhage, and in the case of 
liver reactions, anorexia, nausea/vomiting, or jaundice. Patients should be advised that, because these signs and symptoms may signal a serious reaction, they must report any occurrence immediately to
their physicians. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use. CARBAMAZEPINE: 
information_for_patients: Patients should be advised that serious skin reactions have been reported in association with carbamazepine extended-release capsules. In the event a skin reaction should 
occur while taking carbamazepine extended-release capsules, patients should consult with their physician immediately (see WARNINGS ). Patients should be advised that anaphylactic reactions and 
angioedema may occur during treatment with carbamazepine extended-release capsules (see WARNINGS ). Advise patients to immediately report signs and symptoms suggesting angioedema (swelling of the 
face, eyes, lips, or tongue, or difficulty in swallowing or breathing) and to stop taking the drug until they have consulted with their healthcare provider. CARBAMAZEPINE: information_for_patients: 
Patients, their caregivers, and families should be counseled that AEDs, including carbamazepine, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert 
for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern 
should be reported immediately to healthcare providers. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use 
of any other prescription or nonprescription medications or herbal products. Caution should be exercised if alcohol is taken in combination with carbamazepine therapy, due to a possible additive 
sedative effect. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks. 
CARBAMAZEPINE: information_for_patients: Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of 
antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 (see Warnings-Usage in Pregnancy ). If necessary, the carbamazepine extended-release capsules can
be opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbamazepine extended-release capsules or their contents should not be crushed or 
chewed. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use of any other prescription or non-prescription 
medication or herbal products. Patients, their caregivers, and families should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior 
to taking carbamazepine extended-release capsules. CARBAMAZEPINE: information_for_patients: See FDA approved Medication Guide.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: pharm_class_pe         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: package_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_set_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: product_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: drug_interactions: When used concomitantly with carbamazepine extended-release capsules, monitoring of concentrations or dosage adjustment of these agents may be necessary: 
When carbamazepine is added to aripiprazole, the aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. If carbamazepine is later withdrawn, the 
aripiprazole dose should be reduced. When carbamazepine is used with tacrolimus, monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are recommended. The use of 
concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. If patients must be coadministered carbamazepine with temsirolimus, an adjustment of temsirolimus dosage 
should be considered. The use of carbamazepine with lapatinib should generally be avoided. CARBAMAZEPINE: drug_interactions: If carbamazepine is started in a patient already taking lapatinib, the dose
of lapatinib should be gradually titrated up. If carbamazepine is discontinued, the lapatinib dose should be reduced. Concomitant use of carbamazepine with nefazodone results in plasma concentrations 
of nefazodone and its active metabolite insufficient to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS ). Monitor 
concentrations of valproate when carbamazepine extended-release capsules are introduced or withdrawn in patients using valproic acid. CARBAMAZEPINE: drug_interactions: In addition, carbamazepine 
causes, or would be expected to cause, decreased levels of, for example, the following drugs, for which monitoring of concentrations or dosage adjustment may be necessary: Acetaminophen, albendazole, 
alprazolam, aprepitant, buprenorphine, apixaban( 6 ), bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, dabigatran( 6 
), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g. CARBAMAZEPINE: drug_interactions: felodipine), doxycycline, edoxaban( 6 ), eslicarbazepine, 
ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine,
oral and other hormonal contraceptives( 2 ), oxcarbazepine, paliperidone, phenytoin( 3 ), praziquantel, protease inhibitors, quetiapine, risperidone, rivaroxaban( 6 ), sertraline, sirolimus, 
tadalafil, theophylline, tiagabine, topiramate, tramadol, triazolam, trazodone CARBAMAZEPINE: drug_interactions: ( 4 ), tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), 
valproate, warfarin (5) , ziprasidone, and zonisamide. ( 2 ) Concomitant use of carbamazepine with hormonal contraceptive products (e.g., oral and levonorgestrel subdermal implant contraceptives) may 
render the contraceptives less effective because the plasma concentrations of the hormones may be decreased. Breakthrough bleeding and unintended pregnancies have been reported with carbamazepine. 
Alternative or back-up methods of contraception should be considered. ( 3 ) Phenytoin has also been reported to increase in the presence of carbamazepine. Careful monitoring of phenytoin plasma levels
following co-medication with carbamazepine is advised.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: warnings: However, in the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. Suicidal Behavior and Ideation 
Antiepileptic drugs (AEDs), including carbamazepine extended-release capsules, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated 
with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 
placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 
95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. CARBAMAZEPINE: warnings: In these trials, which had a median treatment duration of 12 weeks, the estimated
incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case
of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to 
allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted
for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. 
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. CARBAMAZEPINE: warnings: The finding of increased risk with AEDs of varying mechanisms of action 
and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table
1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1 - Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 
Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 
Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0. CARBAMAZEPINE: warnings: 9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in 
clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone 
considering prescribing carbamazepine extended-release capsules or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other 
illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts or behavior. Should suicidal thoughts and behavior emerge 
during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. CARBAMAZEPINE: warnings: Hyponatremia, 
Syndrome of Inappropriate Antidiuretic Hormone Secretion, and Water Intoxication Hyponatremia can occur as a result of treatment with carbamazepine extended-release capsules. In many cases, this 
hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment may be dose-related. Elderly 
patients and patients treated with diuretics are at greater risk of developing hyponatremia. Signs and symptoms of hyponatremia include headache, new or increased seizure frequency, difficulty 
concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Consider discontinuing carbamazepine extended-release capsules in patients with symptomatic 
hyponatremia. Usage in Pregnancy Carbamazepine can cause fetal harm when administered to a pregnant woman.         
SOURCE:CARBAMAZEPINE label

 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT 
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?"
  }
}
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?",
    "drug": "CARBAMAZEPINE"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT 
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?"
  }
}
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of 
myocardial infarction?
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does CARBAMAZEPINE increase or decrease the risk of myocardial infarction?",
    "drug": "CARBAMAZEPINE"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) 
CONTENT: CARBAMAZEPINE: drug_interactions: Chloroquine and Mefloquine Anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine. Thus if a patient has been 
titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with carbamazepine extended-release capsules, it is reasonable to expect that a dose adjustment
may be necessary. CNS Depressants The concomitant use of carbamazepine extended-release capsules and other CNS depressants can increase the risk of respiratory depression, profound sedation, 
hypotension, and syncope. CARBAMAZEPINE: drug_interactions: CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, 
antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. Consider reducing the dose of CNS depressants or 
carbamazepine extended-release capsules when using these drugs concomitantly. Because of its primary CNS effect, caution should be used when carbamazepine extended-release capsules are taken with 
other centrally acting drugs and alcohol. Neuromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, 
rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. CARBAMAZEPINE: drug_interactions: Whether or not carbamazepine has the same effect on other 
nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher. CARBAMAZEPINE: 
precautions: Whether or not carbamazepine has the same effect on other nondepolarizing agents is unknown. Patients should be monitored closely for more rapid recovery from neuromuscular blockade than 
expected, and infusion rate requirements may be higher. Carcinogenesis, Mutagenesis, Impairment of Fertility: Administration of carbamazepine to Sprague-Dawley rats for two years in the diet at doses 
of 25, 75, and 250 mg/kg/day (low dose approximately 0.2 times the maximum human daily dose of 1,200 mg on a mg/m 2 basis), resulted in a dose-related increase in the incidence of hepatocellular 
tumors in females and of benign interstitial cell adenomas in the testes of males. Carbamazepine must, therefore, be considered to be carcinogenic in Sprague-Dawley rats. Bacterial and mammalian 
mutagenicity studies using carbamazepine produced negative results. CARBAMAZEPINE: precautions: The significance of these findings relative to the use of carbamazepine in humans is, at present, 
unknown. Usage in Pregnancy (See WARNINGS ) Labor and Delivery The effect of carbamazepine on human labor and delivery is unknown. Nursing Mothers Carbamazepine and its epoxide metabolite are 
transferred to breast milk and during lactation. The concentrations of carbamazepine and its epoxide metabolite are approximately 50% of the maternal plasma concentration. Because of the potential for
serious adverse reactions in nursing infants from carbamazepine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to 
the mother. CARBAMAZEPINE: pediatric_use: Pediatric Use Substantial evidence of carbamazepine effectiveness for use in the management of children with epilepsy (see INDICATIONS for specific seizure 
types) is derived from clinical investigations performed in adults and from studies in several in vitro systems which support the conclusion that (1) the pathogenic mechanisms underlying seizure 
propagation are essentially identical in adults and children, and (2) the mechanism of action of carbamazepine in treating seizures is essentially identical in adults and children. Taken as a whole, 
this information supports a conclusion that the generally acceptable therapeutic range of total carbamazepine in plasma (i.e., 4 to 12 mcg/mL) is the same in children and adults. The evidence 
assembled was primarily obtained from short-term use of carbamazepine. The safety of carbamazepine in children has been systematically studied up to 6 months. No longer term data from clinical trials 
is available.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: information_for_patients: Information for Patients Patients should be informed of the availability of a Medication Guide and they should be instructed to read the Medication 
Guide before taking carbamazepine extended-release capsules. Patients should be made aware of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic 
reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy and petechial or purpuric hemorrhage, and in the case of 
liver reactions, anorexia, nausea/vomiting, or jaundice. Patients should be advised that, because these signs and symptoms may signal a serious reaction, they must report any occurrence immediately to
their physicians. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use. CARBAMAZEPINE: 
information_for_patients: Patients should be advised that serious skin reactions have been reported in association with carbamazepine extended-release capsules. In the event a skin reaction should 
occur while taking carbamazepine extended-release capsules, patients should consult with their physician immediately (see WARNINGS ). Patients should be advised that anaphylactic reactions and 
angioedema may occur during treatment with carbamazepine extended-release capsules (see WARNINGS ). Advise patients to immediately report signs and symptoms suggesting angioedema (swelling of the 
face, eyes, lips, or tongue, or difficulty in swallowing or breathing) and to stop taking the drug until they have consulted with their healthcare provider. CARBAMAZEPINE: information_for_patients: 
Patients, their caregivers, and families should be counseled that AEDs, including carbamazepine, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert 
for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern 
should be reported immediately to healthcare providers. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use 
of any other prescription or nonprescription medications or herbal products. Caution should be exercised if alcohol is taken in combination with carbamazepine therapy, due to a possible additive 
sedative effect. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks. 
CARBAMAZEPINE: information_for_patients: Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of 
antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 (see Warnings-Usage in Pregnancy ). If necessary, the carbamazepine extended-release capsules can
be opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbamazepine extended-release capsules or their contents should not be crushed or 
chewed. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use of any other prescription or non-prescription 
medication or herbal products. Patients, their caregivers, and families should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior 
to taking carbamazepine extended-release capsules. CARBAMAZEPINE: information_for_patients: See FDA approved Medication Guide.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: pharm_class_pe         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: package_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_set_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: product_ndc         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: openfda: spl_id         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: drug_interactions: When used concomitantly with carbamazepine extended-release capsules, monitoring of concentrations or dosage adjustment of these agents may be necessary: 
When carbamazepine is added to aripiprazole, the aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. If carbamazepine is later withdrawn, the 
aripiprazole dose should be reduced. When carbamazepine is used with tacrolimus, monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are recommended. The use of 
concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. If patients must be coadministered carbamazepine with temsirolimus, an adjustment of temsirolimus dosage 
should be considered. The use of carbamazepine with lapatinib should generally be avoided. CARBAMAZEPINE: drug_interactions: If carbamazepine is started in a patient already taking lapatinib, the dose
of lapatinib should be gradually titrated up. If carbamazepine is discontinued, the lapatinib dose should be reduced. Concomitant use of carbamazepine with nefazodone results in plasma concentrations 
of nefazodone and its active metabolite insufficient to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS ). Monitor 
concentrations of valproate when carbamazepine extended-release capsules are introduced or withdrawn in patients using valproic acid. CARBAMAZEPINE: drug_interactions: In addition, carbamazepine 
causes, or would be expected to cause, decreased levels of, for example, the following drugs, for which monitoring of concentrations or dosage adjustment may be necessary: Acetaminophen, albendazole, 
alprazolam, aprepitant, buprenorphine, apixaban( 6 ), bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, dabigatran( 6 
), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g. CARBAMAZEPINE: drug_interactions: felodipine), doxycycline, edoxaban( 6 ), eslicarbazepine, 
ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine,
oral and other hormonal contraceptives( 2 ), oxcarbazepine, paliperidone, phenytoin( 3 ), praziquantel, protease inhibitors, quetiapine, risperidone, rivaroxaban( 6 ), sertraline, sirolimus, 
tadalafil, theophylline, tiagabine, topiramate, tramadol, triazolam, trazodone CARBAMAZEPINE: drug_interactions: ( 4 ), tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), 
valproate, warfarin (5) , ziprasidone, and zonisamide. ( 2 ) Concomitant use of carbamazepine with hormonal contraceptive products (e.g., oral and levonorgestrel subdermal implant contraceptives) may 
render the contraceptives less effective because the plasma concentrations of the hormones may be decreased. Breakthrough bleeding and unintended pregnancies have been reported with carbamazepine. 
Alternative or back-up methods of contraception should be considered. ( 3 ) Phenytoin has also been reported to increase in the presence of carbamazepine. Careful monitoring of phenytoin plasma levels
following co-medication with carbamazepine is advised.         
SOURCE:CARBAMAZEPINE label


CONTENT: CARBAMAZEPINE: warnings: However, in the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. Suicidal Behavior and Ideation 
Antiepileptic drugs (AEDs), including carbamazepine extended-release capsules, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated 
with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 
placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 
95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. CARBAMAZEPINE: warnings: In these trials, which had a median treatment duration of 12 weeks, the estimated
incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case
of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to 
allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted
for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. 
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. CARBAMAZEPINE: warnings: The finding of increased risk with AEDs of varying mechanisms of action 
and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table
1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1 - Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 
Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 
Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0. CARBAMAZEPINE: warnings: 9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in 
clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone 
considering prescribing carbamazepine extended-release capsules or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other 
illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts or behavior. Should suicidal thoughts and behavior emerge 
during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. CARBAMAZEPINE: warnings: Hyponatremia, 
Syndrome of Inappropriate Antidiuretic Hormone Secretion, and Water Intoxication Hyponatremia can occur as a result of treatment with carbamazepine extended-release capsules. In many cases, this 
hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment may be dose-related. Elderly 
patients and patients treated with diuretics are at greater risk of developing hyponatremia. Signs and symptoms of hyponatremia include headache, new or increased seizure frequency, difficulty 
concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Consider discontinuing carbamazepine extended-release capsules in patients with symptomatic 
hyponatremia. Usage in Pregnancy Carbamazepine can cause fetal harm when administered to a pregnant woman.         
SOURCE:CARBAMAZEPINE label

 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.AGENT 
*(orchestrator-myocardial infarction-CARBAMAZEPINE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

The justification for this response is that I have attempted to consult the FDAHandler multiple times to inquire about the relationship between CARBAMAZEPINE and the risk of myocardial infarction. 
However, I have not received any response from FDAHandler. Without the specific information from FDA label data, I cannot provide a reliable answer to the question of whether CARBAMAZEPINE increases 
or decreases the risk of myocardial infarction. Therefore, the answer must be "DO-NOT-KNOW" due to the lack of available data.
